Science and Research

Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)

Multiplex immunofluorescence and immunohistochemistry (mIF/IHC) are increasingly employed antibody-based technologies that use tissue sparingly and facilitate the detection of co-localized or neighboring biomarkers. Specifically, these platforms enable spatial analyses of the tumor microenvironment as well as extended applications, for example, describing normal tissue anatomy, autoimmunity, infectious diseases, etc. mIF/IHC has greatly enhanced biomarker discovery efforts, and a growing number of studies suggest superiority to traditional IHC. Standardization of staining approaches, reporting of image analysis strategies and resultant data is critical for facilitating cross-study comparisons, validation, deployment, and generalization of findings. To address this challenge, The Society for Immunotherapy of Cancer (SITC) previously published two articles providing best practice guidelines for mIF/IHC staining, image analysis, and data sharing. Here, SITC convened stakeholders to develop the third article in the series, a consensus checklist for scientific reporting of mIF/IHC data to support and complement the best practice guidelines. The checklist includes critical components of mIF/IHC applications to be defined within publications such as detailed descriptions of analytical validation; image acquisition, selection, and registration methods; and cell clustering and spatial analysis strategies, amongst others. Such information will help with data reproducibility and comparison across studies towards future drug and assay development.

  • Sater, S.
  • Bifulco, C. B.
  • Rodriguez-Canales, J.
  • Yeong, J.
  • Akturk, G.
  • Angelo, M.
  • Ballesteros-Merino, C.
  • Bankhead, P.
  • Basu, S.
  • Blando, J. M.
  • Brajkovic, S.
  • Cassano, M.
  • Chen, B. J.
  • Coskun, A. F.
  • Cottrell, T. R.
  • De Andrea, C. E.
  • Edwards, R. H.
  • Egelston, C.
  • Engle, L. L.
  • Ernstoff, M. S.
  • Fan, R.
  • Feldman, M.
  • Fox, B. A.
  • Galon, J.
  • Gartrell, R.
  • Gnjatic, S.
  • Green, B. F.
  • Gulley, Jl Md
  • Hellebust, A.
  • Hewitt, S.
  • Hollmann, T. J.
  • Horn, L. A.
  • Howat, W. J.
  • Hoyt, C. C.
  • Jensen, S. M.
  • Kulasinghe, A.
  • Lassoued, W.
  • Lott, S.
  • Mansfield, J.
  • Marwitz, S.
  • Netto, G.
  • Page, D. B.
  • Parra, E.
  • Rimm, D. L.
  • Rodig, S. J.
  • Salgado, R.
  • Schapiro, D.
  • Schalper, Ka Md
  • Sunshine, J. C.
  • Surace, M. J.
  • Szalay, A. S.
  • Thurin, M.
  • Villasboas, J. C.
  • Wharton, K.
  • Wistuba,, II
  • Yearley, J. H.
  • Yuan, Y.
  • Zaki, G.
  • Ziai, J.
  • Taube, J. M.

Keywords

  • Humans
  • *Immunohistochemistry/methods/standards
  • *Neoplasms/immunology/therapy/diagnosis
  • *Immunotherapy/methods/standards
  • *Fluorescent Antibody Technique/methods/standards
  • Tumor Microenvironment
  • *Biomarkers, Tumor
  • Biomarker
  • Immunotherapy
  • Pathology
  • Tumor microenvironment - TME
Publication details
DOI: 10.1136/jitc-2025-012280
Journal: J Immunother Cancer
Number: 12
Work Type: Original
Location: ARCN
Disease Area: LC
Partner / Member: FZB
Access-Number: 41423269


chevron-down